-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128

Benzinga·08/06/2026 15:55:06
Listen to the news
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.